Search

Displaying results 5691 - 5700 of 9333 in total
  1. Drug

    BGB-DXP593

    go.drugbank.com/drugs/DB16357
    Investigational

    With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)) by BeiGene. … [L27401] It is currently being investigated against COVID-19 in the clinical trial NCT04551898 (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants

  2. Drug

    AZD2389

    go.drugbank.com/drugs/DB22104
    Investigational

    NCT06973005: A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants).

  3. Drug

    Nicotinamide adenine dinucleotide phosphate

    go.drugbank.com/drugs/DB03461
    Experimental

    A coenzyme composed of ribosylnicotinamide 5'-phosphate (NMN) coupled by pyrophosphate linkage to the 5'-phosphate adenosine 2',5'-bisphosphate.

  4. Drug

    Anatibant

    go.drugbank.com/drugs/DB05038
    Experimental

    It is developed for the for the treatment of traumatic brain injury (TBI).

  5. Drug

    BHV-1310

    go.drugbank.com/drugs/DB22674
    Experimental

    BHV-1310 is a IgG<sub>1,2,4</sub> selective degrader being investigated for the treatment of Grave's disease.

  6. Drug

    Disoxaril

    go.drugbank.com/drugs/DB08726
    Experimental

    This compound belongs to the phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.

  7. Drug

    BHV-1300

    go.drugbank.com/drugs/DB22673
    Investigational

    BHV-1300 is a IgG<sub>1,2,4</sub> selective degrader being investigated for the treatment of Grave's disease.

  8. Drug

    MIV-701

    go.drugbank.com/drugs/DB05736
    Experimental

    MIV-701 is a selective, potent inhibitor of the protease Cathepsin K. It is developed for the treatment of osteoporosis.

  9. Drug

    CHF 4227

    go.drugbank.com/drugs/DB05882
    Experimental

    The compound has a high receptor affinity and has shown promising efficacy in the prevention of bone loss in animal models of osteoporosis. … Additionally, the compound has shown no uterotrophic activity suggesting a potential therapeutic advantage over drugs normally used in postmenopausal therapy.

  10. Drug

    NV-18

    go.drugbank.com/drugs/DB05886
    Experimental

    of the gall bladder). … NV-18 is a product of the Novogen diphenolic synthetic analogue program that is creating drugs with diverse activities against specific types of cancer.